Clinical Trial Update: STEMVAC in Patients With Early Stage Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

STEMVAC is being studied in a Phase 2 trial for early-stage triple-negative breast cancer. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• STEMVAC

Snippet

Sponsor: University of Washington | Conditions: Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Status: ACTIVE_NOT_RECRUITING